Free Trial
NASDAQ:TARA

Protara Therapeutics Q1 2025 Earnings Report

Protara Therapeutics logo
$3.16 +0.10 (+3.27%)
Closing price 08/4/2025 04:00 PM Eastern
Extended Trading
$6.10 +2.94 (+93.04%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protara Therapeutics EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.47
Beat/Miss
Beat by +$0.18
One Year Ago EPS
N/A

Protara Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Protara Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Protara Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled on Monday, August 11, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Protara Therapeutics Earnings Headlines

Leaked Gov’t Memo Reveals $100 Trillion Deadline
Only Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, and the deadline is fast-approaching. A new federal plan could legally unlock $100 trillion in U.S. resources... and one $10 stock could lead the charge. Former hedge fund manager Whitney Tilson explains how to act now, before this hits the headlines.
See More Protara Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Protara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protara Therapeutics and other key companies, straight to your email.

About Protara Therapeutics

Protara Therapeutics (NASDAQ:TARA), a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

View Protara Therapeutics Profile

More Earnings Resources from MarketBeat